BlackRock
IPHA

BlackRock’s Innate Pharma IPHA Stock Holding History

BlackRock’s Portfolio IPHA Stock Details IPHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-482,645
Closed -$965K – 5812
2022
Q3 		$965K Sell
482,645
-14,630
-3% -$39.5K ﹤0.01% 4488
2022
Q2 		$1.34M Sell
497,275
-7,133
-1% -$20.8K ﹤0.01% 4412
2022
Q1 		$1.7M Buy
504,408
+108,335
+27% +$400K ﹤0.01% 4458
2021
Q4 		$1.81M Buy
+396,073
New +$2.11M ﹤0.01% 4444

Other funds holding IPHA

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Optiver Holding
Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BlackRock's IPHA Position: Q4 2022 in Review

BlackRock sold out of Innate Pharma (IPHA) in Q4 2022, closing a stake of 482,645 shares — an estimated $965K sold.

BlackRock first reported a position in IPHA in Q4 2021 and held it in 4 quarters. The position peaked at $1.81M in Q4 2021. 11 funds tracked by Wall St. Rank hold IPHA as of Q4 2022.

  • BlackRock reported no remaining Innate Pharma position as of Q4 2022 after selling out during the quarter.
  • BlackRock sold 482,645 Innate Pharma shares in Q4 2022, an estimated $965K.
  • BlackRock first reported a position in Innate Pharma in Q4 2021 and held it in 4 quarters.
  • BlackRock's Innate Pharma position peaked at $1.81M in Q4 2021.
  • 11 funds tracked by Wall St. Rank held Innate Pharma as of Q4 2022.

Based on BlackRock's 13F filing for Q4 2022, filed 13 Feb 2023.